Lead Sponsor

Hanmi Pharmaceutical Company Limited

Age

15 - No limit years

Sex

ALL

Healthy Volunteers

No

•Patients with at least 2 years history of PAR prior to the study
•Positive results of skin prick test
•Patients who provided a signed written informed consent form
•Patients who are able and willing to complete subject diaries
•Patients who agree to maintain consistency in their surroundings throughout the study period

•Patients also with non-allergic rhinitis with different causes.
•Patients with severe asthma.
•History of acute • chronic sinusitis within 1 month of Visit 1
•History of intranasal surgeries within 3 months of Visit 1
•Initiation of immunotherapy or dose modification within 1 month prior to Visit 1
•Upper respiratory infections including cold and systemic infections within 3 weeks of Visit 1.
•Chronic use of tricyclic antidepressants, beta agonists, bronchodilators, etc. that may affect the efficacy of study drug.

Related studies

NCT01425632 · Perennial Allergic Rhinitis

NCT07231861 · Bronchial Asthma, Perennial Allergic Rhinitis

NCT05299086 · Perennial Allergic Rhinitis, Child, Only

NCT00732368 · Perennial Allergic Rhinitis

NCT04874714 · Allergic Rhinoconjunctivitis, Perennial Allergic Rhinitis, and more

Efficacy and Safety of HCP1102 Capsule in Patients With Perennial Allergic Rhinitis